[siRNA in macular degeneration].

Area of Science:

• Ophthalmology
• Molecular Biology
• Pharmacology

Context:

• Ocular angiogenesis is a key factor in various eye diseases.
• Current therapies include aptamers, antibodies, and antibody fragments.
• These approved treatments provide temporary inhibition of vascular growth and permeability.

Purpose:

• To review small interfering RNA (siRNA) as a therapeutic strategy for ocular angiogenesis.
• To discuss mechanisms, molecule design, and clinical applications of siRNA.
• To present initial clinical experiences with siRNA in ophthalmology.

Summary:

• Aptamers, recombinant antibodies, and antibody fragments are approved for ocular angiogenesis by blocking signaling molecules.
• These therapies offer temporary inhibition of neovascularization and vascular permeability.
• Small interfering RNA (siRNA) is being evaluated for post-transcriptional gene silencing via mRNA degradation, offering a potential alternative.

Impact:

• siRNA represents a novel therapeutic approach for sustained inhibition of ocular angiogenesis.
• Understanding siRNA mechanisms and design is crucial for developing effective treatments.
• Clinical data on siRNA in ophthalmology will guide future therapeutic strategies and patient care.